A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943

Part of paid clinical trials in Orlando, Florida.

Sponsor
Eli Lilly and Company
Study ID
NCT06313528
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Not accepted

Interventions

  • LY3437943 — DRUG
    Administered SC
  • Placebo — OTHER
    Administered SC

Study Details

The main purpose of the study is to look at the effect of the study drug compared to placebo on calorie intake, energy metabolism, and appetite. The study will last up to 6 months and may include up to 20 visits.

Key Dates

Start date
Mar 20, 2024
Status verified
Sep 2025
Primary completion
Aug 26, 2025
Completion
Aug 26, 2025

Study Design

Enrollment
85 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: LY3437943
    LY3437943 administered subcutaneously (SC)
  • Placebo Comparator: Placebo
    Placebo administered SC

Primary Outcome Measure

Change from Baseline in Total Calorie Intake at Lunch and Dinner (Combined) [ Time Frame: Baseline up to Week 17 (inclusive) ]

Locations (3)

FacilityCityStateZIPSite coordinators
AdventHealth OrlandoOrlandoFlorida32804-
Pennington Biomedical Research CenterBaton RougeLouisiana70808-
Columbia University Irving Medical CenterNew YorkNew York10032-

Find similar trials in Orlando, FL

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
AdventHealth Orlando· Orlando, FLPennington Biomedical Research Center· Baton Rouge, LAColumbia University Irving Medical Center· New York, NY

Related Studies